Maryam took part in a Compass Pathways phase 2b study of COMP360 psilocybin therapy for treatment-resistant depression. The testimonial was made during the MEP Action Group for the Medical Use of Psychedelics meeting "Innovating Mental Health in the EU Pharma Legislation.